In ACS with multivessel CAD, immediate vs. staged complete revascularization was noninferior for a composite outcome...

Area of Science:

• Cardiology
• Interventional Cardiology
• Clinical Trials

Background:

• Acute coronary syndrome (ACS) with multivessel coronary disease (MVD) requires prompt management.
• The optimal timing for complete revascularization in ACS patients with MVD remains debated.
• Previous studies have yielded conflicting results regarding immediate versus staged revascularization strategies.

Purpose of the Study:

• To determine if immediate complete revascularization is non-inferior to staged complete revascularization in patients with ACS and MVD.
• To compare clinical outcomes between immediate and staged revascularization strategies.

Main Methods:

• A prospective, open-label, non-inferiority, randomized controlled trial (BIOVASC).
• Included patients presenting with ACS and MVD.
• Randomized participants to either immediate or staged complete revascularization.

Main Results:

• Immediate complete revascularization was found to be non-inferior to staged complete revascularization.
• Key adverse cardiovascular events did not significantly differ between the two strategies.
• The study provides robust evidence supporting the safety and efficacy of immediate revascularization.

Conclusions:

• Immediate complete revascularization is a viable and safe strategy for patients with acute coronary syndrome and multivessel coronary disease.
• The findings suggest that timely intervention can be prioritized without compromising patient outcomes.
• This trial contributes significant data to guide clinical decision-making in ACS management.